Global Flow Cytometry in Oncology Market: Focus on Product Type, Technology, Type of Cancer, Applications, End Users, Country Data (16 Countries), and Competitive Landscape - Analysis and Forecast, 2021-2031
Market Report Coverage - Flow Cytometry in Oncology
Market Segmentation
Agilent Technologies, Inc., Apogee Flow Systems Ltd., Becton, Dickinson and Company, bioAffinity Technologies, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cytek Biosciences, Cytognos, S.L., Danaher Corporation, Miltenyi Biotec B.V. & Co. KG, Laboratory Corporation of America Holdings, Luminex Corporation, NeoGenomics Laboratories, Inc., Sony Corporation, and Thermo Fisher Scientific Inc.
Key Questions Answered in this Report:
Our healthcare experts have found flow cytometry in oncology industry to be one of the most rapidly evolving and dynamic markets. The global market for flow cytometry in oncology is predicted to grow at a CAGR of 12.02% over the forecast period 2021-2031. The market is driven by certain factors, including rising incidence of hematological malignancies, increasing fund infusions for hematological malignancies, and growing consumer awareness for tailored therapy and precision medicine.
The market is favored by the developments in the field of cancer diagnostic testing and its attributes such as flow cytometry. Currently, the flow cytometry in oncology industry is witnessing an upsurge due to the rising incidence of hematological malignancies, increasing fund infusions for hematological malignancies, and growing consumer awareness for tailored therapy and precision medicine. Additionally, high adoption of flow cytometry instruments by the end users to conduct cancer diagnosis and therapeutic monitoring are some of the critical factors that are expected to bolster the market growth.
Furthermore, biotechnology companies are focusing on the development of robust flow cytometry solutions for a wide range of applications, including translational research and clinical applications, to support researchers and physicians in unraveling insights pertaining to cellular alterations.
Within the research report, the market is segmented on the basis of product type, technology, type of cancer, application, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the number of cases associated with cancer, particularly hematological malignancies, has created a buzz among the biotechnology companies to further invest in the development of cancer diagnostic solutions such as flow cytometry, further aiding physicians to offer value-based therapeutic outcomes to patients. Becton, Dickinson and Company has been a pioneer in this field and has been a significant competitor in this market due to the presence of a diverse product portfolio and intense market penetration.
On the basis of region, in 2020, North America held the largest share of the flow cytometry in oncology market due to high infusion of funding from the government organizations for conducting cancer research, growing incidence and prevalence of cancer, growing awareness about precision medicine, and increasing awareness about early cancer detection, among others. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period 2021-2031.
Market Segmentation
- Product Type – Assays and Kits, Instruments, Reagents and Consumables, and Software
- Technology – Cell-Based and Bead-Based
- Type of Cancer – Hematological Malignancies (Lymphoma, Leukemia, Myeloma, and Other Hematological Malignancies) and Solid Tumors (Breast Cancer, Prostate Cancer, Colorectal Cancer, Lung Cancer, and Other Solid Tumors)
- Application – Translational Research and Clinical Applications (Screening and Diagnostics, and Treatment Monitoring)
- End User – Diagnostic Laboratories, Hospitals and Healthcare Centers, Academic and Research Institutions, and Other End Users
- North America – U.S., and Canada
- Europe – Germany, U.K., France, Italy, Spain, Netherlands, and Rest-of-Europe
- Asia-Pacific – China, Japan, India, Australia, South Korea, Singapore, and Rest-of-Asia-Pacific
- Latin America – Brazil, Mexico, and Rest-of-Latin America
- Rest-of-the-World
- Rising Incidence of Hematological Malignancies
- Increasing Fund Infusions for Hematological Malignancies
- Growing Consumer Awareness for Tailored Therapy and Precision Medicine
- False Negatives and Positives
- Restricted Specificity Offered by Conventional Flow Cytometry-Based MRD Assessment
- Technological Evolution in the Field of Flow Cytometry
- Growth in Solid Tumor Applications of Flow Cytometry
Agilent Technologies, Inc., Apogee Flow Systems Ltd., Becton, Dickinson and Company, bioAffinity Technologies, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Cytek Biosciences, Cytognos, S.L., Danaher Corporation, Miltenyi Biotec B.V. & Co. KG, Laboratory Corporation of America Holdings, Luminex Corporation, NeoGenomics Laboratories, Inc., Sony Corporation, and Thermo Fisher Scientific Inc.
Key Questions Answered in this Report:
- How is flow cytometry revolutionizing the field of oncology?
- What are the major market drivers, challenges, and opportunities in the global flow cytometry in oncology market?
- What are the underlying structures resulting in the emerging trends within the global flow cytometry in oncology market?
- How is the COVID-19 pandemic impacting the global flow cytometry in oncology ecosystem?
- What are the key development strategies that are being implemented by the major players in order to sustain the competitive market?
- What are the key regulatory implications in developed and developing regions pertaining to the use of flow cytometry in the field of oncology?
- What are the potential entry barriers expected to be faced by the companies willing to enter a particular region?
- How is each segment of the market expected to grow during the forecast period 2021-2031, and what is the anticipated revenue to be generated by each of the segments? Following are the segments:
- Product Type (assays and kits, instruments, reagents and consumables, and software)
- Technology (cell-based and bead-based)
- Type of Cancer (hematological malignancies and solid tumor)
- Application (translational research and clinical applications)
- End User (diagnostic laboratories, hospitals and healthcare clinics, academic and research institutions, and other end users)
- Region (North America, Europe, Asia-Pacific, Latin America, and Rest-of-the-World)
- What are the growth opportunities for the companies in the region of their operation?
- Who are the leading players with significant offerings in the global flow cytometry in oncology market?
- Which companies are anticipated to be highly disruptive in the future, and why?
Our healthcare experts have found flow cytometry in oncology industry to be one of the most rapidly evolving and dynamic markets. The global market for flow cytometry in oncology is predicted to grow at a CAGR of 12.02% over the forecast period 2021-2031. The market is driven by certain factors, including rising incidence of hematological malignancies, increasing fund infusions for hematological malignancies, and growing consumer awareness for tailored therapy and precision medicine.
The market is favored by the developments in the field of cancer diagnostic testing and its attributes such as flow cytometry. Currently, the flow cytometry in oncology industry is witnessing an upsurge due to the rising incidence of hematological malignancies, increasing fund infusions for hematological malignancies, and growing consumer awareness for tailored therapy and precision medicine. Additionally, high adoption of flow cytometry instruments by the end users to conduct cancer diagnosis and therapeutic monitoring are some of the critical factors that are expected to bolster the market growth.
Furthermore, biotechnology companies are focusing on the development of robust flow cytometry solutions for a wide range of applications, including translational research and clinical applications, to support researchers and physicians in unraveling insights pertaining to cellular alterations.
Within the research report, the market is segmented on the basis of product type, technology, type of cancer, application, end users, and region. Each of these segments covers the snapshot of the market over the projected years, the inclination of the market revenue, underlying patterns, and trends by using analytics on the primary and secondary data obtained.
Competitive Landscape
The exponential rise in the number of cases associated with cancer, particularly hematological malignancies, has created a buzz among the biotechnology companies to further invest in the development of cancer diagnostic solutions such as flow cytometry, further aiding physicians to offer value-based therapeutic outcomes to patients. Becton, Dickinson and Company has been a pioneer in this field and has been a significant competitor in this market due to the presence of a diverse product portfolio and intense market penetration.
On the basis of region, in 2020, North America held the largest share of the flow cytometry in oncology market due to high infusion of funding from the government organizations for conducting cancer research, growing incidence and prevalence of cancer, growing awareness about precision medicine, and increasing awareness about early cancer detection, among others. Apart from this, the Asia-Pacific region is anticipated to grow at the fastest CAGR during the forecast period 2021-2031.
EXECUTIVE SUMMARY
1 PRODUCT DEFINITION
1.1 Inclusion and Exclusion
2 MARKET SCOPE
2.1 Scope of the Study
2.2 Key Questions Answered in the Report
3 RESEARCH METHODOLOGY
3.1 Global Flow Cytometry in Oncology Market: Research Methodology
3.2 Data Sources
3.2.1 Primary Data Sources
3.2.2 Secondary Data Sources
3.3 Market Estimation Model
3.4 Criteria for Company Profiling
4 MARKET OVERVIEW
4.1 Market Definition
4.2 Application of Flow Cytometry in Oncology (Hematological vs. Solid Tumors)
4.3 Market Footprint and Growth Potential
4.4 COVID-19 Impact: Global Flow Cytometry in Oncology Market
5 INDUSTRY INSIGHTS
5.1 Overview
5.2 Legal Requirements and Framework in U.S.
5.3 Legal Requirements and Framework in Europe
5.4 Legal Requirements and Framework in Asia-Pacific
5.4.1 China
5.4.2 Japan
6 MARKET DYNAMICS
6.1 Overview
6.2 Impact Analysis
6.3 Market Drivers
6.3.1 Rising Incidence of Hematological Malignancies
6.3.2 Increasing Fund Infusions for Hematological Malignancies
6.3.3 Growing Consumer Awareness for Tailored Therapy and Precision Medicine
6.4 Market Restraints
6.4.1 False Negatives and Positives
6.4.2 Restricted Specificity Offered by Conventional Flow Cytometry-Based MRD Assessment
6.5 Market Opportunities
6.5.1 Technological Evolution in the Field of Flow Cytometry
6.5.1.1 Emergence of Multiparametric Flow Cytometry for Hematologic Malignancies
6.5.1.2 Growing Focus on Next-Generation Flow Cytometry
6.5.2 Growth in Solid Tumor Applications of Flow Cytometry
7 COMPETITIVE LANDSCAPE
7.1 Product Launches
7.2 Synergistic Activities
7.3 Acquisitions
7.4 Product Approvals and Business Expansion Activities
7.5 Market Share Analysis, 2019–2020
7.6 Growth Share Analysis
7.6.1 Growth Share Analysis (by Company)
7.6.2 Growth Share Analysis (by Technology)
7.6.3 Growth Share Analysis (by Type of Cancer)
7.6.4 Growth Share Analysis (by Application)
7.7 Competitive Assessment of Different Technologies Utilized for MRD Testing
8 GLOBAL FLOW CYTOMETRY IN ONCOLOGY MARKET (BY PRODUCT TYPE), $MILLION, 2020-2031
8.1 Overview
8.2 Assays and Kits
8.3 Instruments
8.4 Reagents and Consumables
8.5 Software
9 GLOBAL FLOW CYTOMETRY IN ONCOLOGY MARKET (BY TECHNOLOGY), $MILLION, 2020-2031
9.1 Overview
9.2 Cell-Based
9.3 Bead-Based
10 GLOBAL FLOW CYTOMETRY IN ONCOLOGY MARKET (BY TYPE OF CANCER), $MILLION, 2020-2031
10.1 Overview
10.2 Hematological Malignancies
10.2.1 Lymphoma
10.2.2 Leukemia
10.2.3 Myeloma
10.2.4 Other Hematological Malignancies
10.2.5 Global Flow Cytometry Market for Hematological Malignancies (by Technology)
10.3 Solid Tumors
10.3.1 Breast Cancer
10.3.2 Prostate Cancer
10.3.3 Colorectal Cancer (CRC)
10.3.4 Lung Cancer
10.3.5 Other Solid Tumors
10.3.6 Global Flow Cytometry in Oncology Market for Solid Tumors (by Technology)
11 GLOBAL FLOW CYTOMETRY IN ONCOLOGY MARKET (BY APPLICATION), $MILLION, 2020-2031
11.1 Overview
11.2 Translational Research
11.3 Clinical Applications
11.3.1 Screening and Diagnostics
11.3.2 Treatment Monitoring
12 GLOBAL FLOW CYTOMETRY IN ONCOLOGY MARKET (BY END USER), $MILLION, 2020-2031
12.1 Overview
12.2 Diagnostic Laboratories
12.3 Hospitals and Healthcare Clinics
12.4 Academic and Research Institutions
12.5 Other End Users
13 GLOBAL FLOW CYTOMETRY IN ONCOLOGY MARKET (BY REGION), $MILLION, 2020-2031
13.1 Overview
13.2 North America
13.2.1 U.S.
13.2.2 Canada
13.2.3 North America Flow Cytometry in Oncology Market (by Type of Cancer)
13.3 Europe
13.3.1 Germany
13.3.2 U.K.
13.3.3 France
13.3.4 Italy
13.3.5 Spain
13.3.6 Netherlands
13.3.7 Rest-of-Europe
13.3.8 Europe Flow Cytometry in Oncology Market (by Type of Cancer)
13.4 Asia-Pacific (APAC)
13.4.1 China
13.4.2 Japan
13.4.3 India
13.4.4 Australia
13.4.5 South Korea
13.4.6 Singapore
13.4.7 Rest-of-Asia-Pacific (RoAPAC)
13.4.8 Asia-Pacific Flow Cytometry in Oncology Market (by Type of Cancer)
13.5 Latin America (LATAM0
13.5.1 Brazil
13.5.2 Mexico
13.5.3 Rest-of-Latin America (RoLA)
13.5.4 Latin America Flow Cytometry in Oncology Market (by Type of Cancer)
13.6 Rest-of-the-World (RoW)
13.6.1 Rest-of-the-World Flow Cytometry in Oncology Market (by Type of Cancer)
14 COMPANY PROFILES
14.1 Overview
14.2 Agilent Technologies, Inc.
14.2.1 Company Overview
14.2.2 Role of Agilent Technologies, Inc. in the Global Flow Cytometry in Oncology Market
14.2.3 Financials
14.2.4 Key Insights About Financial Health of the Company
14.2.5 SWOT Analysis
14.3 Apogee Flow Systems Ltd.
14.3.1 Company Overview
14.3.2 Role of Apogee Flow Systems Ltd. in the Global Flow Cytometry in Oncology Market
14.3.3 SWOT Analysis
14.4 Becton, Dickinson and Company
14.4.1 Company Overview
14.4.2 Role of Becton, Dickinson and Company in the Global Flow Cytometry in Oncology Market
14.4.3 Financials
14.4.4 Key Insights About Financial Health of the Company
14.4.5 SWOT Analysis
14.5 bioAffinity Technologies, Inc.
14.5.1 Company Overview
14.5.2 Role of bioAffinity Technologies, Inc. in the Global Flow Cytometry in Oncology Market
14.5.3 SWOT Analysis
14.6 Bio-Rad Laboratories, Inc.
14.6.1 Company Overview
14.6.2 Role of Bio-Rad Laboratories, Inc. in the Global Flow Cytometry in Oncology Market
14.6.3 Financials
14.6.4 Key Insights About Financial Health of the Company
14.6.5 SWOT Analysis
14.7 Bio-Techne Corporation
14.7.1 Company Overview
14.7.2 Role of Bio-Techne Corporation in the Global Flow Cytometry in Oncology Market
14.7.3 Financials
14.7.4 Key Insights About Financial Health of the Company
14.7.5 SWOT Analysis
14.8 Cytek Biosciences
14.8.1 Company Overview
14.8.2 Role of Cytek Biosciences in the Global Flow Cytometry in Oncology Market
14.8.3 SWOT Analysis
14.9 Cytognos, S.L.
14.9.1 Company Overview
14.9.2 Role of Cytognos, S.L. in the Global Flow Cytometry in Oncology Market
14.9.3 SWOT Analysis
14.1 Danaher Corporation
14.10.1 Company Overview
14.10.2 Role of Danaher Corporation in the Global Flow Cytometry in Oncology Market
14.10.3 Financials
14.10.4 Key Insights About Financial Health of the Company
14.10.5 SWOT Analysis
14.11 Miltenyi Biotec B.V. & Co. KG
14.11.1 Company Overview
14.11.2 Role of Miltenyi Biotec B.V. & Co. KG in the Global Flow Cytometry in Oncology Market
14.11.3 SWOT Analysis
14.12 Laboratory Corporation of America Holdings
14.12.1 Company Overview
14.12.2 Role of Laboratory Corporation of America Holdings in the Global Flow Cytometry in Oncology Market
14.12.3 Financials
14.12.4 SWOT Analysis
14.13 Luminex Corporation
14.13.1 Company Overview
14.13.2 Role of Luminex Corporation in the Global Flow Cytometry in Oncology Market
14.13.3 Financials
14.13.4 Key Insights About Financial Health of the Company
14.13.5 SWOT Analysis
14.14 NeoGenomics Laboratories, Inc.
14.14.1 Company Overview
14.14.2 Role of NeoGenomics Laboratories, Inc. in the Global Flow Cytometry in Oncology Market
14.14.3 Financials
14.14.4 Key Insights about Financial Health of the Company
14.14.5 SWOT Analysis
14.15 Sony Corporation
14.15.1 Company Overview
14.15.2 Role of Sony Corporation in the Global Flow Cytometry in Oncology Market
14.15.3 Financials
14.15.4 Key Insights About Financial Health of the Company
14.15.5 SWOT Analysis
14.16 Thermo Fisher Scientific Inc.
14.16.1 Company Overview
14.16.2 Role of Thermo Fisher Scientific Inc. in the Global Flow Cytometry in Oncology Market
14.16.3 Financials
14.16.4 Key Insights About Financial Health of the Company
14.16.5 SWOT Analysis
1 PRODUCT DEFINITION
1.1 Inclusion and Exclusion
2 MARKET SCOPE
2.1 Scope of the Study
2.2 Key Questions Answered in the Report
3 RESEARCH METHODOLOGY
3.1 Global Flow Cytometry in Oncology Market: Research Methodology
3.2 Data Sources
3.2.1 Primary Data Sources
3.2.2 Secondary Data Sources
3.3 Market Estimation Model
3.4 Criteria for Company Profiling
4 MARKET OVERVIEW
4.1 Market Definition
4.2 Application of Flow Cytometry in Oncology (Hematological vs. Solid Tumors)
4.3 Market Footprint and Growth Potential
4.4 COVID-19 Impact: Global Flow Cytometry in Oncology Market
5 INDUSTRY INSIGHTS
5.1 Overview
5.2 Legal Requirements and Framework in U.S.
5.3 Legal Requirements and Framework in Europe
5.4 Legal Requirements and Framework in Asia-Pacific
5.4.1 China
5.4.2 Japan
6 MARKET DYNAMICS
6.1 Overview
6.2 Impact Analysis
6.3 Market Drivers
6.3.1 Rising Incidence of Hematological Malignancies
6.3.2 Increasing Fund Infusions for Hematological Malignancies
6.3.3 Growing Consumer Awareness for Tailored Therapy and Precision Medicine
6.4 Market Restraints
6.4.1 False Negatives and Positives
6.4.2 Restricted Specificity Offered by Conventional Flow Cytometry-Based MRD Assessment
6.5 Market Opportunities
6.5.1 Technological Evolution in the Field of Flow Cytometry
6.5.1.1 Emergence of Multiparametric Flow Cytometry for Hematologic Malignancies
6.5.1.2 Growing Focus on Next-Generation Flow Cytometry
6.5.2 Growth in Solid Tumor Applications of Flow Cytometry
7 COMPETITIVE LANDSCAPE
7.1 Product Launches
7.2 Synergistic Activities
7.3 Acquisitions
7.4 Product Approvals and Business Expansion Activities
7.5 Market Share Analysis, 2019–2020
7.6 Growth Share Analysis
7.6.1 Growth Share Analysis (by Company)
7.6.2 Growth Share Analysis (by Technology)
7.6.3 Growth Share Analysis (by Type of Cancer)
7.6.4 Growth Share Analysis (by Application)
7.7 Competitive Assessment of Different Technologies Utilized for MRD Testing
8 GLOBAL FLOW CYTOMETRY IN ONCOLOGY MARKET (BY PRODUCT TYPE), $MILLION, 2020-2031
8.1 Overview
8.2 Assays and Kits
8.3 Instruments
8.4 Reagents and Consumables
8.5 Software
9 GLOBAL FLOW CYTOMETRY IN ONCOLOGY MARKET (BY TECHNOLOGY), $MILLION, 2020-2031
9.1 Overview
9.2 Cell-Based
9.3 Bead-Based
10 GLOBAL FLOW CYTOMETRY IN ONCOLOGY MARKET (BY TYPE OF CANCER), $MILLION, 2020-2031
10.1 Overview
10.2 Hematological Malignancies
10.2.1 Lymphoma
10.2.2 Leukemia
10.2.3 Myeloma
10.2.4 Other Hematological Malignancies
10.2.5 Global Flow Cytometry Market for Hematological Malignancies (by Technology)
10.3 Solid Tumors
10.3.1 Breast Cancer
10.3.2 Prostate Cancer
10.3.3 Colorectal Cancer (CRC)
10.3.4 Lung Cancer
10.3.5 Other Solid Tumors
10.3.6 Global Flow Cytometry in Oncology Market for Solid Tumors (by Technology)
11 GLOBAL FLOW CYTOMETRY IN ONCOLOGY MARKET (BY APPLICATION), $MILLION, 2020-2031
11.1 Overview
11.2 Translational Research
11.3 Clinical Applications
11.3.1 Screening and Diagnostics
11.3.2 Treatment Monitoring
12 GLOBAL FLOW CYTOMETRY IN ONCOLOGY MARKET (BY END USER), $MILLION, 2020-2031
12.1 Overview
12.2 Diagnostic Laboratories
12.3 Hospitals and Healthcare Clinics
12.4 Academic and Research Institutions
12.5 Other End Users
13 GLOBAL FLOW CYTOMETRY IN ONCOLOGY MARKET (BY REGION), $MILLION, 2020-2031
13.1 Overview
13.2 North America
13.2.1 U.S.
13.2.2 Canada
13.2.3 North America Flow Cytometry in Oncology Market (by Type of Cancer)
13.3 Europe
13.3.1 Germany
13.3.2 U.K.
13.3.3 France
13.3.4 Italy
13.3.5 Spain
13.3.6 Netherlands
13.3.7 Rest-of-Europe
13.3.8 Europe Flow Cytometry in Oncology Market (by Type of Cancer)
13.4 Asia-Pacific (APAC)
13.4.1 China
13.4.2 Japan
13.4.3 India
13.4.4 Australia
13.4.5 South Korea
13.4.6 Singapore
13.4.7 Rest-of-Asia-Pacific (RoAPAC)
13.4.8 Asia-Pacific Flow Cytometry in Oncology Market (by Type of Cancer)
13.5 Latin America (LATAM0
13.5.1 Brazil
13.5.2 Mexico
13.5.3 Rest-of-Latin America (RoLA)
13.5.4 Latin America Flow Cytometry in Oncology Market (by Type of Cancer)
13.6 Rest-of-the-World (RoW)
13.6.1 Rest-of-the-World Flow Cytometry in Oncology Market (by Type of Cancer)
14 COMPANY PROFILES
14.1 Overview
14.2 Agilent Technologies, Inc.
14.2.1 Company Overview
14.2.2 Role of Agilent Technologies, Inc. in the Global Flow Cytometry in Oncology Market
14.2.3 Financials
14.2.4 Key Insights About Financial Health of the Company
14.2.5 SWOT Analysis
14.3 Apogee Flow Systems Ltd.
14.3.1 Company Overview
14.3.2 Role of Apogee Flow Systems Ltd. in the Global Flow Cytometry in Oncology Market
14.3.3 SWOT Analysis
14.4 Becton, Dickinson and Company
14.4.1 Company Overview
14.4.2 Role of Becton, Dickinson and Company in the Global Flow Cytometry in Oncology Market
14.4.3 Financials
14.4.4 Key Insights About Financial Health of the Company
14.4.5 SWOT Analysis
14.5 bioAffinity Technologies, Inc.
14.5.1 Company Overview
14.5.2 Role of bioAffinity Technologies, Inc. in the Global Flow Cytometry in Oncology Market
14.5.3 SWOT Analysis
14.6 Bio-Rad Laboratories, Inc.
14.6.1 Company Overview
14.6.2 Role of Bio-Rad Laboratories, Inc. in the Global Flow Cytometry in Oncology Market
14.6.3 Financials
14.6.4 Key Insights About Financial Health of the Company
14.6.5 SWOT Analysis
14.7 Bio-Techne Corporation
14.7.1 Company Overview
14.7.2 Role of Bio-Techne Corporation in the Global Flow Cytometry in Oncology Market
14.7.3 Financials
14.7.4 Key Insights About Financial Health of the Company
14.7.5 SWOT Analysis
14.8 Cytek Biosciences
14.8.1 Company Overview
14.8.2 Role of Cytek Biosciences in the Global Flow Cytometry in Oncology Market
14.8.3 SWOT Analysis
14.9 Cytognos, S.L.
14.9.1 Company Overview
14.9.2 Role of Cytognos, S.L. in the Global Flow Cytometry in Oncology Market
14.9.3 SWOT Analysis
14.1 Danaher Corporation
14.10.1 Company Overview
14.10.2 Role of Danaher Corporation in the Global Flow Cytometry in Oncology Market
14.10.3 Financials
14.10.4 Key Insights About Financial Health of the Company
14.10.5 SWOT Analysis
14.11 Miltenyi Biotec B.V. & Co. KG
14.11.1 Company Overview
14.11.2 Role of Miltenyi Biotec B.V. & Co. KG in the Global Flow Cytometry in Oncology Market
14.11.3 SWOT Analysis
14.12 Laboratory Corporation of America Holdings
14.12.1 Company Overview
14.12.2 Role of Laboratory Corporation of America Holdings in the Global Flow Cytometry in Oncology Market
14.12.3 Financials
14.12.4 SWOT Analysis
14.13 Luminex Corporation
14.13.1 Company Overview
14.13.2 Role of Luminex Corporation in the Global Flow Cytometry in Oncology Market
14.13.3 Financials
14.13.4 Key Insights About Financial Health of the Company
14.13.5 SWOT Analysis
14.14 NeoGenomics Laboratories, Inc.
14.14.1 Company Overview
14.14.2 Role of NeoGenomics Laboratories, Inc. in the Global Flow Cytometry in Oncology Market
14.14.3 Financials
14.14.4 Key Insights about Financial Health of the Company
14.14.5 SWOT Analysis
14.15 Sony Corporation
14.15.1 Company Overview
14.15.2 Role of Sony Corporation in the Global Flow Cytometry in Oncology Market
14.15.3 Financials
14.15.4 Key Insights About Financial Health of the Company
14.15.5 SWOT Analysis
14.16 Thermo Fisher Scientific Inc.
14.16.1 Company Overview
14.16.2 Role of Thermo Fisher Scientific Inc. in the Global Flow Cytometry in Oncology Market
14.16.3 Financials
14.16.4 Key Insights About Financial Health of the Company
14.16.5 SWOT Analysis
LIST OF TABLES
Table 6.1: Likert Scale
Table 6.2: Impact Analysis of Market Drivers
Table 6.3: Impact Analysis of Market Restraints
Table 6.1: Likert Scale
Table 6.2: Impact Analysis of Market Drivers
Table 6.3: Impact Analysis of Market Restraints
LIST OF FIGURES
Figure 1: Prevalence of Hematological Malignancies in the U.S., 2013-2016
Figure 2: National Cancer Institute (NCI) of the U.S., Fiscal Budget Year-on-Year, 2013-2018
Figure 3: Impact Analysis of Market Drivers and Market Challenges on Global Flow Cytometry in Oncology Market
Figure 4: Global Flow Cytometry in Oncology Market (by Product Type), $Million, 2020 and 2031
Figure 5: Global Flow Cytometry in Oncology Market (by Technology), $Million, 2020 and 2031
Figure 6: Global Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020 and 2031
Figure 7: Global Flow Cytometry in Oncology Market (by Application), $Million, 2020 and 2031
Figure 8: Global Flow Cytometry in Oncology Market (by End User), $Million, 2020 and 2031
Figure 9: Global Flow Cytometry in Oncology: Market Snapshot
Figure 2.1: Market Segmentation of Global Flow Cytometry in Oncology Market
Figure 3.1: Global Flow Cytometry in Oncology Market: Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Global Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 4.2: Global Flow Cytometry in Oncology Market: COVID-19 Impact
Figure 6.1: Global Incidence and Mortality Rate for Individual Hematological Conditions, 2016
Figure 6.2: Estimated New Cases of Hematological Cancer, 2020
Figure 7.1: Share of Key Developments and Strategies, January 2017–May 2021
Figure 7.2: Number of Product Launches (by Company), January 2017–May 2021
Figure 7.3: Share of Synergistic Activities (by Company), January 2017-May 2021
Figure 7.4: Share of Acquisitions (by Company), January 2017–May 2021
Figure 7.5: Market Share Analysis for Global Flow Cytometry in Oncology Market, $Million, 2019 and 2020
Figure 7.6: Growth Share Analysis for Global Flow Cytometry in Oncology Market (by Company), 2020
Figure 7.7: Growth Share Analysis for Global Flow Cytometry in Oncology Market (by Technology), 2020-2031
Figure 7.8: Growth Share Analysis for Global Flow Cytometry in Oncology Market (by Type of Cancer), 2020-2031
Figure 7.9: Growth Share Analysis for Global Flow Cytometry in Oncology Market (by Application), 2020-2031
Figure 7.10: Comparative Assessment of Technologies Used in MRD Testing
Figure 8.1: Global Flow Cytometry in Oncology Market (by Product Type)
Figure 8.2: Global Flow Cytometry in Oncology Market (by Product Type), $Million, 2020 and 2031
Figure 8.3: Global Flow Cytometry in Oncology Market (Assays and Kits), $Million, 2020-2031
Figure 8.4: Global Flow Cytometry in Oncology Market (Instruments), $Million, 2020-2031
Figure 8.5: Global Flow Cytometry in Oncology Market (Reagents and Consumables), $Million, 2020-2031
Figure 8.6: Global Flow Cytometry in Oncology Market (Software), $Million, 2020-2031
Figure 9.1: Global Flow Cytometry in Oncology Market (by Technology)
Figure 9.2: Global Flow Cytometry in Oncology Market (by Technology), $Million, 2020 and 2031
Figure 9.3: Global Flow Cytometry in Oncology Market (Cell-Based), $Million, 2020-2031
Figure 9.4: Global Flow Cytometry in Oncology Market (Bead-Based), $Million, 2020-2031
Figure 10.1: Global Flow Cytometry in Oncology Market (by Type of Cancer)
Figure 10.2: Global Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020 and 2031
Figure 10.3: Global Flow Cytometry in Oncology Market (by Hematological Malignancies), $Million, 2020-2031
Figure 10.4: Global Flow Cytometry in Oncology Market (by Hematological Malignancies), $Million, 2020 and 2031
Figure 10.5: Global Flow Cytometry in Oncology Market (Lymphoma), $Million, 2020-2031
Figure 10.6: Global Flow Cytometry in Oncology Market (Leukemia), $Million, 2020-2031
Figure 10.7: Global Flow Cytometry in Oncology Market (Myeloma), $Million, 2020-2031
Figure 10.8: Global Flow Cytometry in Oncology Market (Other Hematological Malignancies), $Million, 2020-2031
Figure 10.9: Global Flow Cytometry in Oncology Market for Hematological Malignancies (by Technology), $Million, 2020-2031
Figure 10.10: Global Flow Cytometry in Oncology Market (by Solid Tumors), $Million, 2020-2031
Figure 10.11: Global Flow Cytometry in Oncology Market (by Solid Tumors), $Million, 2020 and 2031
Figure 10.12: Global Flow Cytometry in Oncology Market (Breast Cancer), $Million, 2020-2031
Figure 10.13: Global Flow Cytometry in Oncology Market (Prostate Cancer), $Million, 2020-2031
Figure 10.14: Global Flow Cytometry in Oncology Market (Colorectal Cancer), $Million, 2020-2031
Figure 10.15: Global Flow Cytometry in Oncology Market (Lung Cancer), $Million, 2020-2031
Figure 10.16: Global Flow Cytometry in Oncology Market (Other Solid Tumors), $Million, 2020-2031
Figure 10.17: Global Flow Cytometry in Oncology Market for Solid Tumors (by Technology), $Million, 2020-2031
Figure 11.1: Global Flow Cytometry in Oncology Market (by Application)
Figure 11.2: Global Flow Cytometry in Oncology Market (by Application), $Million, 2020-2031
Figure 11.3: Global Flow Cytometry in Oncology Market (Translational Research), $Million, 2020-2031
Figure 11.4: Global Flow Cytometry in Oncology Market (by Clinical Applications), $Million, 2020 and 2031
Figure 11.5: Global Flow Cytometry in Oncology Market (Screening and Diagnostics), $Million, 2020-2031
Figure 11.6: Global Flow Cytometry in Oncology Market (Treatment Monitoring), $Million, 2020-2031
Figure 12.1: Global Flow Cytometry in Oncology Market (by End User)
Figure 12.2: Global Flow Cytometry in Oncology Market (by End User), $Million, 2020-2031
Figure 12.3: Global Flow Cytometry in Oncology Market (Diagnostic Laboratories), $Million, 2020-2031
Figure 12.4: Global Flow Cytometry in Oncology Market (Hospitals and Healthcare Clinics), $Million, 2020-2031
Figure 12.5: Global Flow Cytometry in Oncology Market (Academic and Research Institutions), $Million, 2020-2031
Figure 12.6: Global Flow Cytometry in Oncology Market (Other End Users), $Million, 2020-2031
Figure 13.1: Global Flow Cytometry in Oncology Market (by Region)
Figure 13.2: Global Flow Cytometry in Oncology Market (by Region), $Million, 2020-2031
Figure 13.3: Global Flow Cytometry in Oncology Market (by Region), $Million, 2020-2031
Figure 13.4: North America Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.5: North America: Market Dynamics
Figure 13.6: North America Flow Cytometry in Oncology Market (by Country), $Million, 2020-2031
Figure 13.7: U.S. Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.8: Canada Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.9: North America Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
Figure 13.10: Europe Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.11: Europe: Market Dynamics
Figure 13.12: Europe Flow Cytometry in Oncology Market (by Country), $Million, 2020-2031
Figure 13.13: Germany Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.14: U.K. Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.15: France Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.16: Italy Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.17: Spain Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.18: Netherlands Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.19: Rest-of-Europe Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.20: Europe Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
Figure 13.21: Asia-Pacific Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.22: Asia-Pacific: Market Dynamics
Figure 13.23: APAC Flow Cytometry in Oncology Market (by Country), $Million, 2020-2031
Figure 13.24: China Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.25: Japan Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.26: India Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.27: Australia Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.28: South Korea Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.29: Singapore Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.30: RoAPAC Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.31: APAC Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
Figure 13.32: Latin America Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.33: Latin America: Market Dynamics
Figure 13.34: Latin America Flow Cytometry in Oncology Market (by Country), $Million, 2020-2031
Figure 13.35: Brazil Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.36: Mexico Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.37: RoLA Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.38: LATAM Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
Figure 13.39: Rest-of-the-World Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.40: Rest-of-the-World Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
Figure 14.1: Total Number of Companies Profiles
Figure 14.2: Agilent Technologies, Inc.: Product Portfolio
Figure 14.3: Agilent Technologies, Inc.: Overall Financials, 2018-2020
Figure 14.4: Agilent Technologies, Inc.: Revenue (by Segment), 2018-2020
Figure 14.5: Agilent Technologies, Inc.: Revenue (by Region), 2018-2020
Figure 14.6: Agilent Technologies, Inc.: R&D Expenditure, 2018-2020
Figure 14.7: Agilent Technologies, Inc.: SWOT Analysis
Figure 14.8: Apogee Flow Systems Ltd.: Product Portfolio
Figure 14.9: Apogee Flow Systems Ltd.: SWOT Analysis
Figure 14.10: Becton, Dickinson and Company: Product Portfolio
Figure 14.11: Becton, Dickinson and Company: Overall Financials, 2018-2020
Figure 14.12: Becton, Dickinson and Company: Revenue (by Segment), 2018-2020
Figure 14.13: Becton, Dickinson and Company: Revenue (by Region), 2018-2020
Figure 14.14: Becton, Dickinson and Company: R&D Expenditure, 2018-2020
Figure 14.15: Becton, Dickinson and Company: SWOT Analysis
Figure 14.16: bioAffinity Technologies, Inc.: Product Portfolio
Figure 14.17: bioAffinity Technologies, Inc.: SWOT Analysis
Figure 14.18: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 14.19: Bio-Rad Laboratories, Inc.: Overall Financials, 2018-2020
Figure 14.20: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2018-2020
Figure 14.21: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2018-2020
Figure 14.22: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2018-2020
Figure 14.23: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 14.24: Bio-Techne Corporation: Product Portfolio
Figure 14.25: Bio-Techne Corporation: Overall Financials, 2018-2020
Figure 14.26: Bio-Techne Corporation: Revenue (by Segment), 2018-2020
Figure 14.27: Bio-Techne Corporation: Revenue (by Region), 2018-2020
Figure 14.28: Bio-Techne Corporation: R&D Expenditure, 2018-2020
Figure 14.29: Bio-Techne Corporation: SWOT Analysis
Figure 14.30: Cytek Biosciences: Product Portfolio
Figure 14.31: Cytek Biosciences: SWOT Analysis
Figure 14.32: Cytognos, S.L.: Product Portfolio
Figure 14.33: Cytognos, S.L.: SWOT Analysis
Figure 14.34: Danaher Corporation: Product Portfolio
Figure 14.35: Danaher Corporation: Overall Financials, 2018-2020
Figure 14.36: Danaher Corporation: Revenue (by Segment), 2018-2020
Figure 14.37: Danaher Corporation: Revenue (by Region), 2018-2020
Figure 14.38: Danaher Corporation: R&D Expenditure, 2018-2020
Figure 14.39: Danaher Corporation: SWOT Analysis
Figure 14.40: Miltenyi Biotec B.V. & Co. KG: Product Portfolio
Figure 14.41: Miltenyi Biotec B.V. & Co. KG: SWOT Analysis
Figure 14.42: Laboratory Corporation of America Holdings: Service Portfolio
Figure 14.43: Laboratory Corporation of America Holdings: Overall Financials, 2018-2020
Figure 14.44: Laboratory Corporation of America Holdings: Revenue (by Segment), 2018-2020
Figure 14.45: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 14.46: Luminex Corporation: Product Portfolio
Figure 14.47: Luminex Corporation: Overall Financials, 2018-2020
Figure 14.48: Luminex Corporation: Revenue (by Segment), 2018-2020
Figure 14.49: Luminex Corporation: Revenue (by Region), 2018-2020
Figure 14.50: Luminex Corporation: R&D Expenditure, 2018-2020
Figure 14.51: Luminex Corporation: SWOT Analysis
Figure 14.52: NeoGenomics Laboratories, Inc.: Service Portfolio
Figure 14.53: NeoGenomics Laboratories, Inc.: Overall Financials, 2018-2020
Figure 14.54: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2018-2020
Figure 14.55: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2018-2020
Figure 14.56: NeoGenomics Laboratories, Inc.: SWOT Analysis
Figure 14.57: Sony Corporation: Product Portfolio
Figure 14.58: Sony Corporation: Overall Financials, 2018-2020
Figure 14.59: Sony Corporation: Revenue (by Segment): 2018-2020
Figure 14.60: Sony Corporation: Revenue (by Region), 2018-2020 (E)
Figure 14.61: Sony Corporation: R&D Expenditure, 2018-2020 (E)
Figure 14.62: Sony Corporation: SWOT Analysis
Figure 14.63: Thermo Fisher Scientific, Inc.: Product Portfolio
Figure 14.64: Thermo Fisher Scientific, Inc.: Overall Financials, 2018-2020
Figure 14.65: Thermo Fisher Scientific Inc.: Revenue (by Segment): 2018-2020
Figure 14.66: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020
Figure 14.67: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
Figure 14.68: Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 1: Prevalence of Hematological Malignancies in the U.S., 2013-2016
Figure 2: National Cancer Institute (NCI) of the U.S., Fiscal Budget Year-on-Year, 2013-2018
Figure 3: Impact Analysis of Market Drivers and Market Challenges on Global Flow Cytometry in Oncology Market
Figure 4: Global Flow Cytometry in Oncology Market (by Product Type), $Million, 2020 and 2031
Figure 5: Global Flow Cytometry in Oncology Market (by Technology), $Million, 2020 and 2031
Figure 6: Global Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020 and 2031
Figure 7: Global Flow Cytometry in Oncology Market (by Application), $Million, 2020 and 2031
Figure 8: Global Flow Cytometry in Oncology Market (by End User), $Million, 2020 and 2031
Figure 9: Global Flow Cytometry in Oncology: Market Snapshot
Figure 2.1: Market Segmentation of Global Flow Cytometry in Oncology Market
Figure 3.1: Global Flow Cytometry in Oncology Market: Methodology
Figure 3.2: Primary Research Methodology
Figure 3.3: Bottom-Up Approach (Segment-Wise Analysis)
Figure 3.4: Top-Down Approach (Segment-Wise Analysis)
Figure 4.1: Global Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 4.2: Global Flow Cytometry in Oncology Market: COVID-19 Impact
Figure 6.1: Global Incidence and Mortality Rate for Individual Hematological Conditions, 2016
Figure 6.2: Estimated New Cases of Hematological Cancer, 2020
Figure 7.1: Share of Key Developments and Strategies, January 2017–May 2021
Figure 7.2: Number of Product Launches (by Company), January 2017–May 2021
Figure 7.3: Share of Synergistic Activities (by Company), January 2017-May 2021
Figure 7.4: Share of Acquisitions (by Company), January 2017–May 2021
Figure 7.5: Market Share Analysis for Global Flow Cytometry in Oncology Market, $Million, 2019 and 2020
Figure 7.6: Growth Share Analysis for Global Flow Cytometry in Oncology Market (by Company), 2020
Figure 7.7: Growth Share Analysis for Global Flow Cytometry in Oncology Market (by Technology), 2020-2031
Figure 7.8: Growth Share Analysis for Global Flow Cytometry in Oncology Market (by Type of Cancer), 2020-2031
Figure 7.9: Growth Share Analysis for Global Flow Cytometry in Oncology Market (by Application), 2020-2031
Figure 7.10: Comparative Assessment of Technologies Used in MRD Testing
Figure 8.1: Global Flow Cytometry in Oncology Market (by Product Type)
Figure 8.2: Global Flow Cytometry in Oncology Market (by Product Type), $Million, 2020 and 2031
Figure 8.3: Global Flow Cytometry in Oncology Market (Assays and Kits), $Million, 2020-2031
Figure 8.4: Global Flow Cytometry in Oncology Market (Instruments), $Million, 2020-2031
Figure 8.5: Global Flow Cytometry in Oncology Market (Reagents and Consumables), $Million, 2020-2031
Figure 8.6: Global Flow Cytometry in Oncology Market (Software), $Million, 2020-2031
Figure 9.1: Global Flow Cytometry in Oncology Market (by Technology)
Figure 9.2: Global Flow Cytometry in Oncology Market (by Technology), $Million, 2020 and 2031
Figure 9.3: Global Flow Cytometry in Oncology Market (Cell-Based), $Million, 2020-2031
Figure 9.4: Global Flow Cytometry in Oncology Market (Bead-Based), $Million, 2020-2031
Figure 10.1: Global Flow Cytometry in Oncology Market (by Type of Cancer)
Figure 10.2: Global Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020 and 2031
Figure 10.3: Global Flow Cytometry in Oncology Market (by Hematological Malignancies), $Million, 2020-2031
Figure 10.4: Global Flow Cytometry in Oncology Market (by Hematological Malignancies), $Million, 2020 and 2031
Figure 10.5: Global Flow Cytometry in Oncology Market (Lymphoma), $Million, 2020-2031
Figure 10.6: Global Flow Cytometry in Oncology Market (Leukemia), $Million, 2020-2031
Figure 10.7: Global Flow Cytometry in Oncology Market (Myeloma), $Million, 2020-2031
Figure 10.8: Global Flow Cytometry in Oncology Market (Other Hematological Malignancies), $Million, 2020-2031
Figure 10.9: Global Flow Cytometry in Oncology Market for Hematological Malignancies (by Technology), $Million, 2020-2031
Figure 10.10: Global Flow Cytometry in Oncology Market (by Solid Tumors), $Million, 2020-2031
Figure 10.11: Global Flow Cytometry in Oncology Market (by Solid Tumors), $Million, 2020 and 2031
Figure 10.12: Global Flow Cytometry in Oncology Market (Breast Cancer), $Million, 2020-2031
Figure 10.13: Global Flow Cytometry in Oncology Market (Prostate Cancer), $Million, 2020-2031
Figure 10.14: Global Flow Cytometry in Oncology Market (Colorectal Cancer), $Million, 2020-2031
Figure 10.15: Global Flow Cytometry in Oncology Market (Lung Cancer), $Million, 2020-2031
Figure 10.16: Global Flow Cytometry in Oncology Market (Other Solid Tumors), $Million, 2020-2031
Figure 10.17: Global Flow Cytometry in Oncology Market for Solid Tumors (by Technology), $Million, 2020-2031
Figure 11.1: Global Flow Cytometry in Oncology Market (by Application)
Figure 11.2: Global Flow Cytometry in Oncology Market (by Application), $Million, 2020-2031
Figure 11.3: Global Flow Cytometry in Oncology Market (Translational Research), $Million, 2020-2031
Figure 11.4: Global Flow Cytometry in Oncology Market (by Clinical Applications), $Million, 2020 and 2031
Figure 11.5: Global Flow Cytometry in Oncology Market (Screening and Diagnostics), $Million, 2020-2031
Figure 11.6: Global Flow Cytometry in Oncology Market (Treatment Monitoring), $Million, 2020-2031
Figure 12.1: Global Flow Cytometry in Oncology Market (by End User)
Figure 12.2: Global Flow Cytometry in Oncology Market (by End User), $Million, 2020-2031
Figure 12.3: Global Flow Cytometry in Oncology Market (Diagnostic Laboratories), $Million, 2020-2031
Figure 12.4: Global Flow Cytometry in Oncology Market (Hospitals and Healthcare Clinics), $Million, 2020-2031
Figure 12.5: Global Flow Cytometry in Oncology Market (Academic and Research Institutions), $Million, 2020-2031
Figure 12.6: Global Flow Cytometry in Oncology Market (Other End Users), $Million, 2020-2031
Figure 13.1: Global Flow Cytometry in Oncology Market (by Region)
Figure 13.2: Global Flow Cytometry in Oncology Market (by Region), $Million, 2020-2031
Figure 13.3: Global Flow Cytometry in Oncology Market (by Region), $Million, 2020-2031
Figure 13.4: North America Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.5: North America: Market Dynamics
Figure 13.6: North America Flow Cytometry in Oncology Market (by Country), $Million, 2020-2031
Figure 13.7: U.S. Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.8: Canada Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.9: North America Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
Figure 13.10: Europe Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.11: Europe: Market Dynamics
Figure 13.12: Europe Flow Cytometry in Oncology Market (by Country), $Million, 2020-2031
Figure 13.13: Germany Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.14: U.K. Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.15: France Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.16: Italy Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.17: Spain Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.18: Netherlands Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.19: Rest-of-Europe Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.20: Europe Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
Figure 13.21: Asia-Pacific Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.22: Asia-Pacific: Market Dynamics
Figure 13.23: APAC Flow Cytometry in Oncology Market (by Country), $Million, 2020-2031
Figure 13.24: China Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.25: Japan Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.26: India Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.27: Australia Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.28: South Korea Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.29: Singapore Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.30: RoAPAC Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.31: APAC Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
Figure 13.32: Latin America Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.33: Latin America: Market Dynamics
Figure 13.34: Latin America Flow Cytometry in Oncology Market (by Country), $Million, 2020-2031
Figure 13.35: Brazil Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.36: Mexico Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.37: RoLA Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.38: LATAM Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
Figure 13.39: Rest-of-the-World Flow Cytometry in Oncology Market, $Million, 2020-2031
Figure 13.40: Rest-of-the-World Flow Cytometry in Oncology Market (by Type of Cancer), $Million, 2020-2031
Figure 14.1: Total Number of Companies Profiles
Figure 14.2: Agilent Technologies, Inc.: Product Portfolio
Figure 14.3: Agilent Technologies, Inc.: Overall Financials, 2018-2020
Figure 14.4: Agilent Technologies, Inc.: Revenue (by Segment), 2018-2020
Figure 14.5: Agilent Technologies, Inc.: Revenue (by Region), 2018-2020
Figure 14.6: Agilent Technologies, Inc.: R&D Expenditure, 2018-2020
Figure 14.7: Agilent Technologies, Inc.: SWOT Analysis
Figure 14.8: Apogee Flow Systems Ltd.: Product Portfolio
Figure 14.9: Apogee Flow Systems Ltd.: SWOT Analysis
Figure 14.10: Becton, Dickinson and Company: Product Portfolio
Figure 14.11: Becton, Dickinson and Company: Overall Financials, 2018-2020
Figure 14.12: Becton, Dickinson and Company: Revenue (by Segment), 2018-2020
Figure 14.13: Becton, Dickinson and Company: Revenue (by Region), 2018-2020
Figure 14.14: Becton, Dickinson and Company: R&D Expenditure, 2018-2020
Figure 14.15: Becton, Dickinson and Company: SWOT Analysis
Figure 14.16: bioAffinity Technologies, Inc.: Product Portfolio
Figure 14.17: bioAffinity Technologies, Inc.: SWOT Analysis
Figure 14.18: Bio-Rad Laboratories, Inc.: Product Portfolio
Figure 14.19: Bio-Rad Laboratories, Inc.: Overall Financials, 2018-2020
Figure 14.20: Bio-Rad Laboratories, Inc.: Revenue (by Segment), 2018-2020
Figure 14.21: Bio-Rad Laboratories, Inc.: Revenue (by Region), 2018-2020
Figure 14.22: Bio-Rad Laboratories, Inc.: R&D Expenditure, 2018-2020
Figure 14.23: Bio-Rad Laboratories, Inc.: SWOT Analysis
Figure 14.24: Bio-Techne Corporation: Product Portfolio
Figure 14.25: Bio-Techne Corporation: Overall Financials, 2018-2020
Figure 14.26: Bio-Techne Corporation: Revenue (by Segment), 2018-2020
Figure 14.27: Bio-Techne Corporation: Revenue (by Region), 2018-2020
Figure 14.28: Bio-Techne Corporation: R&D Expenditure, 2018-2020
Figure 14.29: Bio-Techne Corporation: SWOT Analysis
Figure 14.30: Cytek Biosciences: Product Portfolio
Figure 14.31: Cytek Biosciences: SWOT Analysis
Figure 14.32: Cytognos, S.L.: Product Portfolio
Figure 14.33: Cytognos, S.L.: SWOT Analysis
Figure 14.34: Danaher Corporation: Product Portfolio
Figure 14.35: Danaher Corporation: Overall Financials, 2018-2020
Figure 14.36: Danaher Corporation: Revenue (by Segment), 2018-2020
Figure 14.37: Danaher Corporation: Revenue (by Region), 2018-2020
Figure 14.38: Danaher Corporation: R&D Expenditure, 2018-2020
Figure 14.39: Danaher Corporation: SWOT Analysis
Figure 14.40: Miltenyi Biotec B.V. & Co. KG: Product Portfolio
Figure 14.41: Miltenyi Biotec B.V. & Co. KG: SWOT Analysis
Figure 14.42: Laboratory Corporation of America Holdings: Service Portfolio
Figure 14.43: Laboratory Corporation of America Holdings: Overall Financials, 2018-2020
Figure 14.44: Laboratory Corporation of America Holdings: Revenue (by Segment), 2018-2020
Figure 14.45: Laboratory Corporation of America Holdings: SWOT Analysis
Figure 14.46: Luminex Corporation: Product Portfolio
Figure 14.47: Luminex Corporation: Overall Financials, 2018-2020
Figure 14.48: Luminex Corporation: Revenue (by Segment), 2018-2020
Figure 14.49: Luminex Corporation: Revenue (by Region), 2018-2020
Figure 14.50: Luminex Corporation: R&D Expenditure, 2018-2020
Figure 14.51: Luminex Corporation: SWOT Analysis
Figure 14.52: NeoGenomics Laboratories, Inc.: Service Portfolio
Figure 14.53: NeoGenomics Laboratories, Inc.: Overall Financials, 2018-2020
Figure 14.54: NeoGenomics Laboratories, Inc.: Revenue (by Segment), 2018-2020
Figure 14.55: NeoGenomics Laboratories, Inc.: R&D Expenditure, 2018-2020
Figure 14.56: NeoGenomics Laboratories, Inc.: SWOT Analysis
Figure 14.57: Sony Corporation: Product Portfolio
Figure 14.58: Sony Corporation: Overall Financials, 2018-2020
Figure 14.59: Sony Corporation: Revenue (by Segment): 2018-2020
Figure 14.60: Sony Corporation: Revenue (by Region), 2018-2020 (E)
Figure 14.61: Sony Corporation: R&D Expenditure, 2018-2020 (E)
Figure 14.62: Sony Corporation: SWOT Analysis
Figure 14.63: Thermo Fisher Scientific, Inc.: Product Portfolio
Figure 14.64: Thermo Fisher Scientific, Inc.: Overall Financials, 2018-2020
Figure 14.65: Thermo Fisher Scientific Inc.: Revenue (by Segment): 2018-2020
Figure 14.66: Thermo Fisher Scientific Inc.: Revenue (by Region), 2018-2020
Figure 14.67: Thermo Fisher Scientific Inc.: R&D Expenditure, 2018-2020
Figure 14.68: Thermo Fisher Scientific Inc.: SWOT Analysis
